Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Filtros adicionais











País/Região como assunto
Intervalo de ano
1.
Rev Bras Epidemiol ; 22: e190006, 2019 Mar 14.
Artigo em Português, Inglês | MEDLINE | ID: mdl-30892469

RESUMO

INTRODUCTION: The lack of availability of the Therasuit Method by the Unified Health System associated with its high cost has led to the prosecution of this treatment. The study aimed to outline the profile of this judicialization, as well as to estimate the direct costs resulting from compliance with the deferred judicial decisions. METHOD: Weanalyzed the cases submitted to the Court of Justice of Rio de Janeiro between January 2013 and January 2017, in which the Therasuit Method was applied. Demographic, clinical, advocacy and legal data were extracted, as was the timing of the court's decision and the required technology budgets. RESULTS: Atotal of 11 processes was analyzed. The authors had a mean age of 6.8 years and a median of 6, the majority being male, and resident in thestate capital. Quadriparesis was the most reported condition. The gratuity of justice was requested by all, and the Public Defender's Officewas used by 9 of the 11 processes. The judicial decisions at first instance were considered. In all of processes there was application of the legal tool called guardianship. The time of the judicial decision was on average of 266.5 days with a median of 35.5. The deferral index was 90%, totaling an annual direct cost of R$501,894.09. DISCUSSION: The judicialization of this treatment can cause an unforeseen displacement of public funds, transgressing the principles of equity and the integrality of Unified Health System. CONCLUSION: It was observed a high rate of deferred processes, resulting in a high cost spent by the Public Power to attend a small portion of patients.


Assuntos
Paralisia Cerebral/terapia , Custos de Cuidados de Saúde/legislação & jurisprudência , Acesso aos Serviços de Saúde/legislação & jurisprudência , Programas Nacionais de Saúde/legislação & jurisprudência , Direitos do Paciente/legislação & jurisprudência , Modalidades de Fisioterapia/instrumentação , Adolescente , Brasil , Paralisia Cerebral/economia , Criança , Pré-Escolar , Feminino , Acesso aos Serviços de Saúde/economia , Humanos , Masculino , Programas Nacionais de Saúde/economia , Modalidades de Fisioterapia/economia
2.
Rev. bras. epidemiol ; 22: e190006, 2019. tab
Artigo em Português | LILACS-Express | ID: biblio-990727

RESUMO

RESUMO: Introdução: O Método Therasuit possui alto custo e não é disponibilizado pelo Sistema Único de Saúde, o que tem ocasionado a judicialização desse tratamento. O estudo visou traçar o perfil dessa judicialização, bem como estimar os custos diretos decorrentes do cumprimento das decisões judiciais deferidas. Método: Foram analisados processos submetidos ao Tribunal de Justiça do Rio de Janeiro entre janeiro de 2013 e janeiro de 2017, no qual foi solicitado o Método Therasuit. Os dados demográficos, clínicos, advocatícios e jurídicos foram extraídos, assim como o tempo da decisão judicial e os orçamentos da tecnologia requerida. Resultados: O total de 11 processos foi analisado. Os autores tinham uma média de idade de 6,8 anos e mediana de 6, sendo a maioria do sexo masculino e residentes na capital do estado. A quadriparesia foi a condição mais relatada. A gratuidade de justiça foi solicitada por todos, e a Defensoria Pública foi utilizada em 9 dos 11 processos analisados. Foram consideradas as decisões judiciais em primeira instância. O tempo da decisão judicial foi em média de 266,5 dias com uma mediana de 35,5. Em todos houve requerimento da ferramenta jurídica tutela antecipada. O índice de deferimento foi de 90%, totalizando um custo direto anual de R$501.894,09. Discussão: A judicialização desse tratamento pode ocasionar um deslocamento não previsto de verba pública, podendo impactar nos princípios da equidade e na integralidade do Sistema Único de Saúde. Conclusão: Constatou-se elevada taxa de processos deferidos, acarretando um alto custo despendido pelo Poder Público para atender a uma pequena parcela de pacientes.


ABSTRACT: Introduction: The lack of availability of the Therasuit Method by the Unified Health System associated with its high cost has led to the prosecution of this treatment. The study aimed to outline the profile of this judicialization, as well as to estimate the direct costs resulting from compliance with the deferred judicial decisions. Method: Weanalyzed the cases submitted to the Court of Justice of Rio de Janeiro between January 2013 and January 2017, in which the Therasuit Method was applied. Demographic, clinical, advocacy and legal data were extracted, as was the timing of the court's decision and the required technology budgets. Results: Atotal of 11 processes was analyzed. The authors had a mean age of 6.8 years and a median of 6, the majority being male, and resident in thestate capital. Quadriparesis was the most reported condition. The gratuity of justice was requested by all, and the Public Defender's Officewas used by 9 of the 11 processes. The judicial decisions at first instance were considered. In all of processes there was application of the legal tool called guardianship. The time of the judicial decision was on average of 266.5 days with a median of 35.5. The deferral index was 90%, totaling an annual direct cost of R$501,894.09. Discussion: The judicialization of this treatment can cause an unforeseen displacement of public funds, transgressing the principles of equity and the integrality of Unified Health System. Conclusion: It was observed a high rate of deferred processes, resulting in a high cost spent by the Public Power to attend a small portion of patients.

3.
Rev. Assoc. Med. Bras. (1992) ; 64(9): 853-860, Sept. 2018. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-976853

RESUMO

SUMMARY INTRODUCTION Heart failure due to an acute myocardial infarction is a very frequent event, with a tendency to increase according to improvements in the treatment of acute conditions which have led to larger numbers of infarction survivors. OBJECTIVE The aim of this study is to synthesize the evidence, through a systematic review, on efficacy and safety of the device in patients with this basic condition. METHODS Studies published between January 2002 and October 2016 were analysed, having as reference databases Embase, Medline, Cochrane Library, Lilacs, Web of Science and Scopus. The selection of studies, data extraction and methodological quality assessment of studies were examined by two independent reviewers, with disagreements resolved by consensus. RESULTS Only prospective studies without control group were identified. Six studies were included, with averages of 34 participants and follow-up of 13 months. Clinical, functional, hemodynamic and quality of life outcomes were evaluated. The highest mortality rate was 8.4% with 12-month follow-up for unspecified cardiovascular reasons, and heart failure rehospitalization was 29.4% with 36-month follow-up. Statistically significant improvements were found only in some of the studies which evaluating changes in left ventricular volume indices, the distance measured by the six-minute walk test, New York Heart Association functional classification, and quality of life, in pre and post-procedure analysis. CONCLUSIONS The present review indicates that no available quality evidence can assert efficacy and safety of PARACHUTE® in the treatment of heart failure after apical or anterior wall myocardial infarction.


RESUMO INTRODUÇÃO Insuficiência cardíaca após infarto agudo do miocárdio é um evento bastante frequente, que tende a aumentar conforme as melhorias que o tratamento dos quadros agudos têm acarretado a números maiores de sobreviventes de infarto. OBJETIVO A revisão sistemática sumarizou as evidências relativas à eficácia e segurança do dispositivo de partição ventricular (PARACHUTE®) em pacientes com IC pós-IAM apical ou de parede anterior. MÉTODOS Foram analisados estudos publicados entre janeiro de 2002 e outubro de 2016 nas bases Embase, Medline, Colaboração Cochrane, Lilacs, Web of Science e Scopus. A seleção dos estudos, a extração dos dados e a avaliação de qualidade metodológica foram realizadas por dois revisores independentes, com as discordâncias resolvidas por consenso. RESULTADOS Somente estudos prospectivos sem grupo controle foram identificados. Seis estudos foram incluídos, com média de 34 participantes e de follow-up de 13 meses. Foram avaliados desfechos clínicos, funcionais, hemodinâmicos e qualidade de vida. O maior percentual de re-hospitalização por IC foi de 29,4%, com 36 meses de seguimento, e de mortalidade foi de 8,4%, com 12 meses de seguimento, por motivos cardiovasculares não especificados. Melhorias estatisticamente significantes foram constatadas em alguns dos estudos que avaliaram mudanças nos índices de volume do ventrículo esquerdo, distância medida pelo teste de caminhada de 6 minutos, classificação funcional da New York Heart Association e qualidade de vida, em análises do tipo antes e depois do procedimento. CONCLUSÕES A presente revisão indica que não existem evidências de qualidade disponíveis que permitam afirmar a eficácia e segurança do PARACHUTE® no tratamento da condição de base.

4.
Rev Assoc Med Bras (1992) ; 64(9): 853-860, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30673008

RESUMO

INTRODUCTION: Heart failure due to an acute myocardial infarction is a very frequent event, with a tendency to increase according to improvements in the treatment of acute conditions which have led to larger numbers of infarction survivors. OBJECTIVE: The aim of this study is to synthesize the evidence, through a systematic review, on efficacy and safety of the device in patients with this basic condition. METHODS: Studies published between January 2002 and October 2016 were analysed, having as reference databases Embase, Medline, Cochrane Library, Lilacs, Web of Science and Scopus. The selection of studies, data extraction and methodological quality assessment of studies were examined by two independent reviewers, with disagreements resolved by consensus. RESULTS: Only prospective studies without control group were identified. Six studies were included, with averages of 34 participants and follow-up of 13 months. Clinical, functional, hemodynamic and quality of life outcomes were evaluated. The highest mortality rate was 8.4% with 12-month follow-up for unspecified cardiovascular reasons, and heart failure rehospitalization was 29.4% with 36-month follow-up. Statistically significant improvements were found only in some of the studies which evaluating changes in left ventricular volume indices, the distance measured by the six-minute walk test, New York Heart Association functional classification, and quality of life, in pre and post-procedure analysis. CONCLUSIONS: The present review indicates that no available quality evidence can assert efficacy and safety of PARACHUTE® in the treatment of heart failure after apical or anterior wall myocardial infarction.


Assuntos
Insuficiência Cardíaca/etiologia , Insuficiência Cardíaca/terapia , Infarto do Miocárdio/complicações , Próteses e Implantes/normas , Desenho de Equipamento , Humanos , Qualidade de Vida , Reprodutibilidade dos Testes , Resultado do Tratamento , Disfunção Ventricular Esquerda/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA